An updated reappraisal of dupilumab in children and adolescents with moderate–severe atopic dermatitis
Pediatric Allergy and Immunology · 2024
DOI: 10.1111/pai.14181 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pediatric Allergy and Immunology, 2024. Verfasst von Giorgio Ciprandi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Clinic, Casa di Cura Villa Montallegro, Genoa, Italy. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 99 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Atopic dermatitis (AD) is still a demanding challenge in clinical practice. Type 2 inflammation is the most common inflammatory pathway in children and adolescents with AD. Anti‐inflammatory drugs, mainly corticosteroids (CS) and immunomodulant agents are the primary therapeutic approach to dampening type 2 inflammation. However, AD patients may require long‐term high CS doses or drug combinations with possibly significant adverse effects to achieve and maintain disease control. In this regard, the advent of biologics constituted a breakthrough in managing this condition. Dupilumab is a monoclonal antibody directed against the IL‐4 receptor α‐subunit (IL‐4Rα), antagonizing both IL‐4 and IL‐13 and is approved for pediatric severe AD. This review presents and discusses the most recent published studies on dupilumab in children and adolescents with AD. There is convincing evidence that dupilumab is safe and effective in managing AD. It can reduce skin lesions and associated itching, reduce the need for additional medications, and improve disease control and quality of life. However, a thorough diagnostic pathway is mandatory, especially considering the different AD phenotypes. The ideal eligible candidate is a child or adolescent with AD requiring systemic treatment because of severe clinical manifestations and impaired quality of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Allergy Clinic, Casa di Cura Villa Montallegro, Genoa, Italy.
- Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
- Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.
- Allergy Center, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
- Department of Woman, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", Naples, Italy.
- Pediatric Dermatology Unit, Department of Women's and Child's Health (SDB), University of Padua, Padua, Italy.
ORCID-Profile: Giorgio Ciprandi, Gian Luigi Marseglia
Zitieren
APA
Ciprandi, G., Licari, A., Tosca, M. A., Miraglia Del Giudice, M., Belloni Fortina, A., & Marseglia, G. L. (2024). An updated reappraisal of dupilumab in children and adolescents with moderate–severe atopic dermatitis. Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.14181
Vancouver
Ciprandi G, Licari A, Tosca MA, Miraglia Del Giudice M, Belloni Fortina A, Marseglia GL. An updated reappraisal of dupilumab in children and adolescents with moderate–severe atopic dermatitis. Pediatric Allergy and Immunology. 2024. doi:10.1111/pai.14181
BibTeX
@article{Ciprandi2024,
author = {Ciprandi, Giorgio and Licari, Amelia and Tosca, Maria Angela and Miraglia Del Giudice, Michele and Belloni Fortina, Anna and Marseglia, Gian Luigi},
title = {An updated reappraisal of dupilumab in children and adolescents with moderate–severe atopic dermatitis},
journal = {Pediatric Allergy and Immunology},
year = {2024},
doi = {10.1111/pai.14181}
}
EUVIMED